MotherToBaby

Medications and More during pregnancy and breastfeeding

Search

866.626.6847

Labetalol

Selected References:

  • Bateman BT, et al. 2016. Late pregnancy β Blocker exposure and risks of neonatal hypoglycemia and bradycardia. Pediatrics; 138(3). Pii: e20160731.
  • Beau A-B, et al. 2014. Safety of oseltamivir during pregnancy: a comparative study using the EFEMERIS database. BJOG. 121(7):895-900.
  • Caton AR, et al. 2009. Antihypertensive medication use during pregnancy and the risk of cardiovascular malformations. Hypertension; 54(1):63-70.
  • Chan WS, et al. 2010. Neurocognitive development of children following in-utero exposure to labetalol for maternal hypertension: a cohort study using a prospectively collected database. Hypertens Pregnancy. 29(3):271-83.
  • Clark, S. M. et al. 2015. A review of oral labetalol and nifedipine in mild to moderate hypertension in pregnancy. Seminars in perinatology, 39(7), 548–555.
  • Crooks B et al. 1998. Adverse neonatal effects of maternal labetalol treatment. Archives of disease in childhood. Fetal and neonatal edition, 79(2), F150–F151.
  • Davis RL, et al. 2011. Risks of congenital malformations and perinatal events among infants exposed to calcium channel and beta-blockers during pregnancy. Pharmacoepidemiol Drug Saf.; 20(2):138-45.
  • Duan, L. et al. 2017. β-Blocker Exposure in Pregnancy and Risk of Fetal Cardiac Anomalies. JAMA Internal Medicine, 177(6), 885–887.
  • Firoz T, et al. 2014. Community Level Interventions for Pre-eclampsia (CLIP) Working Group. Oral antihypertensive therapy for severe hypertension in pregnancy and postpartum: a systematic review. BJOG. 121(10):1210-8.
  • Fitton, C. A. et al. 2017. In-utero exposure to antihypertensive medication and neonatal and child health outcomes: a systematic review. Journal of hypertension, 35(11), 2123–2137.
  • Lam, MTC & Dierking, E. 2017. Intensive care unit issues in eclampsia and HELLP syndrome. Int J Crit Illn Inj Sci, 7:136–141
  • Magee LA, et al. 2022. The 2021 International Society for the Study of Hypertension in Pregnancy classification, diagnosis & management recommendations for international practice. Pregnancy hypertension, 27: 148-169.
  • Magee, LA. et al. 2015. Labetalol for hypertension in pregnancy. Expert Opinion on Drug Safety, 14(3), 453–461.
  • O’Meara, J, White, WB. 1988. Ejaculatory failure and urinary dysfunction secondary to labetalol. J Urol 139:371-2.
  • Pasker-de Jong PC, et al. 2010. Antihypertensive treatment during pregnancy and functional development at primary school age in a historical cohort study. BJOG. 117(9):1080-6.
  • Reddy, S., & Jim, B. 2019. Hypertension and Pregnancy: Management and Future Risks. Advances in Chronic Kidney Disease, 26(2), 137–145. https://doi.org/10.1053/j.ackd.2019.03.017
  • Ruys TP, et al. 2014. Cardiac medication during pregnancy, data from the ROPAC. Int J Cardiol. 15; 177(1):124-8.
  • Tanaka K, et al. 2016. Beta-blockers and fetal growth restriction in pregnant women with cardiovascular disease. Circ J; 80(10):2221-6.
  • Van Zutphen AR, et al. Maternal hypertension, medication use, and hypospadias in the National Birth Defects Prevention Study. Obstet Gynecol. 123:309-317.
  • Xie RH, et al. 2014. Association between labetalol use for hypertension in pregnancy and adverse infant outcomes. Eur J Obstet Gynecol Reprod Biol. 175:124-8.
  • Xie RH, et al. 2014. Beta-blockers increase the risk of being born small for gestational age or of being institutionalized during infancy. BJOG. 121(9):1090-6.
  • Yakoob, M. Y. et al. The risk of congenital malformations associated with exposure to β-blockers early in pregnancy: a meta-analysis. Hypertension (Dallas, Tex.: 1979), 62(2), 375–381.
  • Yang, X. et al. 2019. Distinct outcomes of labetalol exposed infants: case reports and systematic review. The Journal of Maternal-Fetal & Neonatal Medicine, 1–7.

This website is supported by the Health Resources and Services Administration (HRSA) of the U.S. Department of Health and Human Services (HHS) as part of an award totaling $6,000,000 with zero percentage financed with non-governmental sources. The contents are those of the author(s) and do not necessarily represent the official views of, nor an endorsement by, HRSA, HHS, or the U.S. Government.